Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 vs Chemotherapy in Advanced Urothelial Carcinoma
NCT06738251Phase 3Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SHR-A2102 in urothelial carcinoma (UC) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Progression-free Survival and Overall Survival. Started Feb 2025; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06738251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738251.